AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026
Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survivalAstraZeneca’s supplemental Biologics License
AstraZeneca's cancer medicine got fast track review from the FDA. Watch for the final decision in late 2026 to see if it works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.